Platelet BioGenesis, the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, announced today the addition of Dr. Richard Murray, president and CEO of Jounce Therapeutics, to its board of directors. Read more >>
The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant concern – an inadequate supply of platelets at blood centers across the country. Read more >>
Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, and Scaled Biolabs (Scaled) announced the two firms are collaborating to optimize PBG’s unique production process for making human platelets, or PLTs+™. The agreement was announced at the SynBioBeta 2018 biology summit. Read more >>
Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of platelet-based therapeutics, announced it has moved into brand new lab space in Cambridge, MA. Located next to MIT, the newly renovated property puts Platelet BioGenesis in the heart of the most dynamic biotech cluster in the world. Read more >>
Cambridge, Massachusetts-based Platelet Biogenesis was awarded a two-year, $3.5 million grant from the U.S. Department of Defense. The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets. Read more >>
Platelet BioGenesis, the leader in the production of functional human platelets (PLTs+TM) from stem cells and the development of platelet-based therapeutics, announced it has recruited a team of world-renowned experts to its newly formed scientific advisory board. Read more >>
Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>
Platelet BioGenesis, a pioneer in the production of functional human platelets (PLTs+™) from stem cells, announced it has licensed patents related to induced pluripotent stem cells (“iPS cells”) from iPS Academia Japan’s patent portfolio. This non-exclusive agreement moves Platelet BioGenesis closer to its goal of producing functional human platelets at commercial scale. Read more >>
About 100 iCons scholars and applicants gathered in the Integrative Learning Center of UMass Amherst on Nov 9, 2017 for the annual iCons Fall Integrative Workshop. They came to hear Dr. Jonathan Thon tell the story of how his start-up company Platelet Biogenesis came to be. Integrated Concentration in Science (iCons) Program Director Justin Fermann introduced Thon to the crowd, telling the iCons students “we are here because we have work to do, and he’s got some problems we […]
Platelets are the bandaids of the bloodstream. Every year more than two million people in the US receive platelet transfusions as part of cancer treatment, transplants and surgery. Unfortunately, platelets are at high risk of bacterial or viral contamination, and have a very short shelf life. We spoke to Sven Karlsson of Platelet BioGenesis, an exciting company and winner of the BioPharm America startup competition, that has developed a ex vivo system for generating immune compatible platelets on demand. […]
